Last reviewed · How we verify

OnabotulinumtoxinA (BOTOX®)

Naval Medical Center Camp Lejeune · Phase 3 active Small molecule

OnabotulinumtoxinA (BOTOX®) is a Botulinum toxin Small molecule drug developed by Naval Medical Center Camp Lejeune. It is currently in Phase 3 development for Cervical dystonia, Blepharospasm, Strabismus. Also known as: Botox.

OnabotulinumtoxinA blocks the release of acetylcholine at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

OnabotulinumtoxinA blocks the release of acetylcholine at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Strabismus.

At a glance

Generic nameOnabotulinumtoxinA (BOTOX®)
Also known asBotox
SponsorNaval Medical Center Camp Lejeune
Drug classBotulinum toxin
TargetSNAP-25 (synaptosome-associated protein of 25 kDa)
ModalitySmall molecule
Therapeutic areaNeurology, Dermatology, Aesthetics
PhasePhase 3

Mechanism of action

The drug is a botulinum toxin serotype A that irreversibly cleaves SNAP-25, a protein essential for acetylcholine vesicle release. This prevents neuromuscular transmission and results in localized muscle weakness or paralysis lasting 3–4 months. The effect is reversible as the body gradually regenerates new nerve terminals.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about OnabotulinumtoxinA (BOTOX®)

What is OnabotulinumtoxinA (BOTOX®)?

OnabotulinumtoxinA (BOTOX®) is a Botulinum toxin drug developed by Naval Medical Center Camp Lejeune, indicated for Cervical dystonia, Blepharospasm, Strabismus.

How does OnabotulinumtoxinA (BOTOX®) work?

OnabotulinumtoxinA blocks the release of acetylcholine at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

What is OnabotulinumtoxinA (BOTOX®) used for?

OnabotulinumtoxinA (BOTOX®) is indicated for Cervical dystonia, Blepharospasm, Strabismus, Chronic migraine, Overactive bladder.

Who makes OnabotulinumtoxinA (BOTOX®)?

OnabotulinumtoxinA (BOTOX®) is developed by Naval Medical Center Camp Lejeune (see full Naval Medical Center Camp Lejeune pipeline at /company/naval-medical-center-camp-lejeune).

Is OnabotulinumtoxinA (BOTOX®) also known as anything else?

OnabotulinumtoxinA (BOTOX®) is also known as Botox.

What drug class is OnabotulinumtoxinA (BOTOX®) in?

OnabotulinumtoxinA (BOTOX®) belongs to the Botulinum toxin class. See all Botulinum toxin drugs at /class/botulinum-toxin.

What development phase is OnabotulinumtoxinA (BOTOX®) in?

OnabotulinumtoxinA (BOTOX®) is in Phase 3.

What are the side effects of OnabotulinumtoxinA (BOTOX®)?

Common side effects of OnabotulinumtoxinA (BOTOX®) include Headache, Neck pain, Injection site pain or bruising, Muscle weakness (localized), Ptosis (eyelid drooping), Dry mouth.

What does OnabotulinumtoxinA (BOTOX®) target?

OnabotulinumtoxinA (BOTOX®) targets SNAP-25 (synaptosome-associated protein of 25 kDa) and is a Botulinum toxin.

Related